Wall Street analysts predict that SCYNEXIS Inc (NASDAQ:SCYX) will post ($0.37) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have made estimates for SCYNEXIS’s earnings. SCYNEXIS posted earnings per share of ($0.52) in the same quarter last year, which would indicate a positive year-over-year growth rate of 28.8%. The business is scheduled to issue its next earnings results on Monday, May 8th.

On average, analysts expect that SCYNEXIS will report full-year earnings of ($1.73) per share for the current year. For the next financial year, analysts expect that the business will post earnings of ($2.16) per share. Zacks Investment Research’s EPS averages are a mean average based on a survey of research analysts that that provide coverage for SCYNEXIS.

SCYX has been the topic of several recent research reports. Zacks Investment Research downgraded SCYNEXIS from a “hold” rating to a “sell” rating in a report on Wednesday, December 28th. Needham & Company LLC reaffirmed a “buy” rating and set a $10.00 target price on shares of SCYNEXIS in a research note on Friday, March 3rd. HC Wainwright reaffirmed a “buy” rating and set a $14.00 target price on shares of SCYNEXIS in a research note on Wednesday, February 22nd. Guggenheim reaffirmed a “buy” rating and set a $15.00 target price on shares of SCYNEXIS in a research note on Friday, March 3rd. Finally, Aegis initiated coverage on SCYNEXIS in a research note on Tuesday, January 31st. They issued a “buy” rating and a $7.00 price objective on the stock. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $10.56.

Shares of SCYNEXIS (NASDAQ:SCYX) traded down 2.31% during trading on Monday, reaching $2.54. The company had a trading volume of 131,486 shares. SCYNEXIS has a 52-week low of $1.74 and a 52-week high of $5.51. The firm has a 50-day moving average price of $2.72 and a 200-day moving average price of $3.33. The company’s market capitalization is $64.84 million.

COPYRIGHT VIOLATION WARNING: “SCYNEXIS Inc (SCYX) Expected to Post Earnings of -$0.37 Per Share” was published by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright law. The original version of this news story can be viewed at https://www.watchlistnews.com/scynexis-inc-scyx-expected-to-post-earnings-of-0-37-per-share/1206132.html.

An institutional investor recently bought a new position in SCYNEXIS stock. Perceptive Advisors LLC purchased a new position in SCYNEXIS Inc (NASDAQ:SCYX) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 171,185 shares of the company’s stock, valued at approximately $546,000. Perceptive Advisors LLC owned approximately 0.71% of SCYNEXIS as of its most recent SEC filing. Hedge funds and other institutional investors own 47.81% of the company’s stock.

SCYNEXIS Company Profile

SCYNEXIS, Inc is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains.

5 Day Chart for NASDAQ:SCYX

Get a free copy of the Zacks research report on SCYNEXIS (SCYX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for SCYNEXIS Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.